{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:04:09Z","timestamp":1779372249496,"version":"3.53.1"},"reference-count":71,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Malignant pleural mesothelioma (MPM) is an aggressive and rare malignant pleural tumor. Methods: MPM patients diagnosed in Beijing Chaoyang Hospital and Beijing Tongren Hospital were the focus of this study. We collected and analyzed the histological, radiological, and metabolic features of MPM patients. At the same time, Cox univariable and multivariable analyses were used to explore the laboratory risk factors affecting the prognosis of MPM patients. Results: A total of 129 MPM patients were included in this study. MPM includes three main histological subtypes: epithelioid, sarcomatoid and biphasic. Among them, epithelial subtypes accounted for the highest proportion. Calretinin, Wilms\u2019 tumor gene (WT1), cytokeratin 5\/6 (CK5\/6), and D2-40 were the most useful mesothelial markers to support a MPM diagnosis. The imaging features of MPM patients are pleural thickening and pleural effusion. In PET-CT, the affected pleura showed obvious high uptake of tracer, and the degree was related to the specific subtype. The median follow-up time was 55.0 (30.0, 94.0) months. A total of 92 (71.3%) patients died during follow-up. The median survival time of patients was 21.0 (9.0, 48.0) months. The Cox multivariable analysis showed that age [hazard ratio (HR), 1.824; 95% confidence interval (CI) 1.159\u20132.872; p = 0.009; uncorrected], ESR (HR, 2.197; 95% CI 1.318\u20133.664; p = 0.003; with Bonferroni correction), lymphocytes (HR, 0.436; 95% CI 0.258\u20130.737; p = 0.002; with Bonferroni correction), platelets (HR, 1.802; 95% CI 1.084\u20132.997; p = 0.023; uncorrected) and total protein (HR, 0.625; 95% CI 0.394\u20130.990; p = 0.045; uncorrected) were independent risk factors for prognosis, after adjusting for confounding factors. Conclusions: Age, ESR, lymphocytes, platelets and total protein may be related to the prognosis of MPM patients. Summarizing the histological, radiological, and metabolic features of MPM patients in the two centers can increase clinicians\u2019 understanding of this rare tumor.<\/jats:p>","DOI":"10.3390\/medicina58121874","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T01:36:02Z","timestamp":1671500162000},"page":"1874","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma"],"prefix":"10.3390","volume":"58","author":[{"given":"Yuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuerong","family":"LiZhu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1289\/ehp.1002845","article-title":"Global magnitude of reported and unreported mesothelioma","volume":"119","author":"Park","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018, GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.21037\/atm.2020.03.58","article-title":"Malignant pleural mesothelioma: Between pragmatism and hope","volume":"8","author":"Migliore","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_5","first-page":"491","article-title":"Malignant pleural mesothelioma: An epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3322\/caac.21490","article-title":"Improving patient and caregiver outcomes in oncology: Team-based, timely, and targeted palliative care","volume":"68","author":"Hui","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","first-page":"573","article-title":"A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_8","first-page":"288","article-title":"Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery","volume":"14","author":"Harris","year":"2019","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_9","first-page":"1240","article-title":"Introduction to the 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","article-title":"Predicting survival in malignant pleural effusion: Development and validation of the LENT prognostic score","volume":"69","author":"Clive","year":"2014","journal-title":"Thorax"},{"key":"ref_13","first-page":"587","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_14","first-page":"1925","article-title":"Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma","volume":"16","author":"Yeap","year":"2021","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_15","first-page":"1898","article-title":"Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy","volume":"7","author":"Tagawa","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2015.07.014","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma","volume":"90","author":"Yamagishi","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Vogl, M., Rosenmayr, A., Bohanes, T., Scheed, A., Brndiar, M., Stubenberger, E., and Ghanim, B. (2021). Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation. Cancers, 13.","DOI":"10.3390\/cancers13040658"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/JTO.0000000000000399","article-title":"Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer","volume":"10","author":"Cannon","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ye, K., Xiao, M., Li, Z., He, K., Wang, J., Zhu, L., Xiong, W., Zhong, Z., and Tang, Y. (2022). Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non-muscle-invasive bladder cancer. Cancer Med.","DOI":"10.1002\/cam4.5284"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"902955","DOI":"10.3389\/fonc.2022.902955","article-title":"The clinical relevance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic obstructive pulmonary disease with lung cancer","volume":"12","author":"Ma","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2021.04.025","article-title":"Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions","volume":"156","author":"Larose","year":"2021","journal-title":"Lung cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/SLA.0000000000004306","article-title":"Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma: Encouraging Results and Novel Prognostic Implications Based on Experience in 355 Consecutive Patients","volume":"275","author":"Lapidot","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: Advances and new agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"684110","DOI":"10.3389\/fonc.2021.684110","article-title":"Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1\/PD-L1 Immune-Checkpoint Blockade","volume":"11","author":"Nardone","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/bjc.2012.354","article-title":"Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma","volume":"107","author":"Kinoshita","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"142425","DOI":"10.1155\/2014\/142425","article-title":"Inflammation-based scores: A new method for patient-targeted strategies and improved perioperative outcome in cancer patients","volume":"2014","author":"Bugada","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2796.1991.tb00356.x","article-title":"Blood analyses and survival in symptom- and survey-detected lung cancer patients","volume":"229","author":"Hannisdal","year":"1991","journal-title":"J. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.21037\/tlcr-22-171","article-title":"A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer","volume":"11","author":"Cao","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1055-9965.EPI-18-0376","article-title":"Cancer Risk and Prognosis after a Hospital Contact for an Elevated Erythrocyte Sedimentation Rate","volume":"28","author":"Kornum","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-309007","article-title":"Adolescent body mass index and erythrocyte sedimentation rate in relation to colorectal cancer risk","volume":"65","author":"Kantor","year":"2016","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma","volume":"11","author":"Bille","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group, B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/ejcts\/ezv422","article-title":"Specimen weight and volume: Important predictors of survival in malignant pleural mesothelioma","volume":"49","author":"Kircheva","year":"2016","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000499677","article-title":"The Value of COX-2, NF-\u03baB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma","volume":"42","author":"Yin","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fimmu.2014.00116","article-title":"Autoimmunity as a double agent in tumor killing and cancer promotion","volume":"5","author":"Toomer","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Desage, A.L., Karpathiou, G., Peoc\u2019h, M., and Froudarakis, M.E. (2021). The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review. Cancers, 13.","DOI":"10.3390\/cancers13133205"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Napoli, F., Listi, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., and Righi, L. (2021). Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13112564"},{"key":"ref_40","first-page":"173","article-title":"Functional analysis of mononuclear cells infiltrating into tumors: Lysis of autologous human tumor cells by cultured infiltrating lymphocytes","volume":"47","author":"Rabinowich","year":"1987","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.mpa.0000188305.90290.50","article-title":"Decreased total lymphocyte counts in pancreatic cancer: An index of adverse outcome","volume":"32","author":"Fogar","year":"2006","journal-title":"Pancreas"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.it.2007.05.008","article-title":"NKT cells in immunoregulation of tumor immunity: A new immunoregulatory axis","volume":"28","author":"Terabe","year":"2007","journal-title":"Trends Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","article-title":"Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection","volume":"25","author":"Gao","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccr.2005.04.014","article-title":"De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent","volume":"7","author":"Korets","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/JTO.0b013e3182037b76","article-title":"The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: Emphasis on non-small cell lung cancer","volume":"6","author":"Bremnes","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6775","DOI":"10.2147\/CMAR.S318728","article-title":"One-Year Mortality in Patients with Cancer Cachexia: Association with Albumin and Total Protein","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1136\/bmjspcare-2020-002296","article-title":"The patient-generated subjective global assessment is a promising screening tool for cancer cachexia","volume":"12","author":"Cong","year":"2022","journal-title":"BMJ Support Palliat. Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Xu, L.L., Yang, Y., Wang, Z., Wang, X.J., Tong, Z.H., and Shi, H.Z. (2018). Malignant pleural mesothelioma: Diagnostic value of medical thoracoscopy and long-term prognostic analysis. BMC Pulm. Med., 18.","DOI":"10.1186\/s12890-018-0619-3"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.21037\/jtd.2017.10.125","article-title":"The pathological and molecular diagnosis of malignant pleural mesothelioma: A literature review","volume":"10","author":"Ali","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3389\/fonc.2020.01742","article-title":"The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review","volume":"10","author":"Rozitis","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/modpathol.2012.200","article-title":"Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas","volume":"26","author":"Ordonez","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New Markers for Separating Benign from Malignant Mesothelial Proliferations: Are We There Yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/thoraxjnl-2014-206054","article-title":"Role of CT in assessing pleural malignancy prior to thoracoscopy","volume":"70","author":"Hallifax","year":"2015","journal-title":"Thorax"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ejrad.2008.02.004","article-title":"Malignant pleural mesothelioma: Computed tomography and correlation with histology","volume":"70","author":"Seely","year":"2009","journal-title":"Eur. J. Radiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000503239","article-title":"Diagnostic Value of Computed Tomography Imaging Features in Malignant Pleural Mesothelioma","volume":"99","author":"Fortin","year":"2020","journal-title":"Respiration"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1378\/chest.114.3.713","article-title":"Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography","volume":"114","author":"Benard","year":"1998","journal-title":"Chest"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sun, Y., Yu, H., Ma, J., and Lu, P. (2016). The Role of 18F-FDG PET\/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161764"},{"key":"ref_65","first-page":"333","article-title":"Clinical implications of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma","volume":"27","author":"Abe","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lim, J.H., Choi, J.Y., Im, Y., Yoo, H., Jhun, B.W., Jeong, B.H., Park, H.Y., Lee, K., Kim, H., and Kwon, O.J. (2020). Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET\/CT scan in patients with malignant pleural mesothelioma. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229299"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/icvts\/ivz303","article-title":"18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: Diagnostic and prognostic performance and its correlation to pathological results","volume":"30","author":"Lococo","year":"2020","journal-title":"Interact Cardiovasc Thorac. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JTO.0b013e3181cbf465","article-title":"Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma","volume":"5","author":"Tan","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00066-015-0901-8","article-title":"Tomotherapy PET-guided dose escalation: A dosimetric feasibility study for patients with malignant pleural mesothelioma","volume":"192","author":"Maggio","year":"2016","journal-title":"Strahlenther Onkol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1053\/j.semnuclmed.2022.04.008","article-title":"A Role for PET\/CT in response assessment of malignant pleural mesothelioma","volume":"52","author":"Sandach","year":"2022","journal-title":"Semin. Nucl. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/12\/1874\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:44:20Z","timestamp":1760147060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/12\/1874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["medicina58121874"],"URL":"https:\/\/doi.org\/10.3390\/medicina58121874","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]}}}